Cancer Screening and Diagnosis with Exosomes
Exosomics was established in 2011 as spinoff of HansaBioMed OU for the exploitation of technologies applied to oncological diagnostics. Exosomics has been located at the Medical Research Center of the Fondazione Toscana Life Sciences since 2012 and represents a very innovative company in the field of oncology. The main company interests are new platforms for cancer screening, diagnostics for personalized therapies and diagnostic monitoring of oncological patients. Exosomics employs the properties of exosomes as marker vehicles in peripheral blood in order to obtain relevant diagnostic information. As Antonio Chiesi, company founder and CEO, explains in his interview, the exosomes are lipid nanoparticles released in the biological fluids from all cells and, in particular, from cancer tissues, which transmit the disease’s markers (proteins and nucleic acids) into the blood. Through content analysis of these nanoparticles, it is possible to obtain an accurate cancer diagnosis.
The aim of Exosomics Siena is to revolutionize the oncological diagnostics field through the use of screening assays for precision medicine with a high innovation content.
The company has recently acquired an important international partner, LONZA, which invested in technologies and in the innovative approach proposed by Exosomics to improve cancer diagnostics. The company also cooperates with many national and international clinical groups on the development and validation of its own diagnostic products and on the optimization of innovative technologies in the field of liquid biopsy.

For more information: www.exosomics.eu